Mycosis Fungoides Clinical Trials 2023

What are the top hospitals conducting mycosis fungoides research?

When it comes to clinical trials for mycosis fungoides, a rare type of lymphoma that primarily affects the skin, several top-notch hospitals in the United States are leading the way. In Saint Louis, Washington University School of Medicine stands out with six ongoing trials focused on this condition and an impressive history of 12 completed studies since their first trial in 2009. Meanwhile, Memorial Sloan Kettering Cancer Center in New york City is making significant strides as well, currently conducting four active mycosis fungoides trials and having recorded ten such trials overall since 2009.

In Houston, two prestigious medical centers are also contributing to advancements in mycosis fungoides research. M D Anderson Cancer Center boasts four ongoing clinical trials for this condition and has conducted nine previous studies dating back to their initial trial in 1998. Similarly, the City of Hope Medical Center in Duarte is actively involved with four ongoing mycosis fungoides trials and holds a notable record of ten past studies starting from their first investigation in 1997.

Additionally joining these respected institutions is another branch of MD Anderson Cancer Center located in Houston itself where three current clinical tests involving mycosis fungoides patients are underway; they have previously contributed through eight dedicated investigations tracing back seventeen years prior till initiating it's pioneering trail on aforementioned disease cases back around2004.

These hospitals serve as beacons of hope for individuals battling this rare form of cancer by not only providing cutting-edge treatment options but also contributing valuable insights into understanding and managing this complex disease. The collaborative efforts among these renowned institutions drive us closer towards improved therapies while offering optimism to patients worldwide affected by mycosis fungoides

Which are the best cities for mycosis fungoides clinical trials?

When it comes to mycosis fungoides clinical trials, several cities stand out as leading centers for research and innovation. New york City boasts 14 active trials, focusing on treatments such as Pembrolizumab, MT-101, and IPH4102. Houston, Texas follows closely behind with 10 ongoing studies investigating Brentuximab vedotin, MT-101, and Radiation Therapy. Duarte, California is also a key location with 8 active trials studying MT-101, Pembrolizumab administered using the Sofusa® DoseConnect™ system, and a tetanus-CMV fusion peptide vaccine. Additionally, Saint Louis in Missouri offers 8 active trials exploring treatments like Talimogene Laherparepvec and Anti-ICOS Monoclonal Antibody MEDI-570. Lastly Philadelphia in Pennsylvania has 7 active trials focused on IPH4102 among other interventions. These cities serve as hubs of cutting-edge research in the field of mycosis fungoides clinical trials offering hope for improved treatment options for patients battling this condition.

Which are the top treatments for mycosis fungoides being explored in clinical trials?

Exciting developments are underway in the exploration of clinical trials for mycosis fungoides, a type of lymphoma. Leading the charge is pembrolizumab, currently being tested in three active trials and having participated in eight all-time mycosis fungoides trials since its listing in 2014. Additionally, cemiplimab has shown promise with one ongoing trial and being listed as recently as 2023. Another contender to watch is brentuximab vedotin, which has participated in four past trials and continues to be explored through one active trial after debuting in 2011. Lastly, MT-101 shows potential with one ongoing trial following its introduction into the scene just last year (2021). The dedication to advancing treatment options for mycosis fungoides offers hope for patients facing this challenging condition.

What are the most recent clinical trials for mycosis fungoides?

Promising advancements are underway in the realm of mycosis fungoides, with recent clinical trials providing renewed hope for patients. Among these trials is fenretinide, a Phase 1 study that explores the potential benefits of this treatment specifically tailored to address mycosis fungoides. Additionally, a Phase 2 trial offers participants access to an innovative treatment arm designed to tackle this condition's unique challenges head-on. Furthermore, another ongoing Phase 1 trial aims to evaluate a new cohort and its response to therapy for mycosis fungoides. Notably, cemiplimab demonstrates potential as both a Phase 1 and Phase 2 intervention in combating this disease since its availability earlier this year. Lastly, the efficacy of mogamulizumab—an investigational drug—has been investigated through a promising Phase 2 study conducted last October. These groundbreaking clinical trials bring optimism towards improving outcomes for individuals afflicted by mycosis fungoides.

What mycosis fungoides clinical trials were recently completed?

In recent years, two notable clinical trials investigating potential treatments for mycosis fungoides have reached completion. The National Cancer Institute sponsored a trial focusing on Mogamulizumab, which concluded in February 2020. Additionally, they conducted a trial exploring the effectiveness of rhIL-15 therapy, which wrapped up in June 2019. These completed studies mark important steps forward in our understanding and management of mycosis fungoides, providing valuable insights that may contribute to improved treatment strategies for patients with this challenging condition.